JP2024503689A5 - - Google Patents

Info

Publication number
JP2024503689A5
JP2024503689A5 JP2023542844A JP2023542844A JP2024503689A5 JP 2024503689 A5 JP2024503689 A5 JP 2024503689A5 JP 2023542844 A JP2023542844 A JP 2023542844A JP 2023542844 A JP2023542844 A JP 2023542844A JP 2024503689 A5 JP2024503689 A5 JP 2024503689A5
Authority
JP
Japan
Prior art keywords
tablet
formulation according
tablet formulation
present
maximum concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023542844A
Other languages
English (en)
Japanese (ja)
Other versions
JP7862402B2 (ja
JP2024503689A (ja
Filing date
Publication date
Priority claimed from GBGB2100470.0A external-priority patent/GB202100470D0/en
Application filed filed Critical
Publication of JP2024503689A publication Critical patent/JP2024503689A/ja
Publication of JP2024503689A5 publication Critical patent/JP2024503689A5/ja
Application granted granted Critical
Publication of JP7862402B2 publication Critical patent/JP7862402B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023542844A 2021-01-14 2022-01-14 リジニラゾールの固形錠剤剤形 Active JP7862402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
GB2100470.0 2021-01-14
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (3)

Publication Number Publication Date
JP2024503689A JP2024503689A (ja) 2024-01-26
JP2024503689A5 true JP2024503689A5 (cg-RX-API-DMAC7.html) 2026-04-02
JP7862402B2 JP7862402B2 (ja) 2026-05-19

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542844A Active JP7862402B2 (ja) 2021-01-14 2022-01-14 リジニラゾールの固形錠剤剤形

Country Status (12)

Country Link
US (1) US12318487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4277604A1 (cg-RX-API-DMAC7.html)
JP (1) JP7862402B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230131253A (cg-RX-API-DMAC7.html)
CN (1) CN116801867A (cg-RX-API-DMAC7.html)
AU (1) AU2022207756B2 (cg-RX-API-DMAC7.html)
CA (1) CA3145677A1 (cg-RX-API-DMAC7.html)
GB (1) GB202100470D0 (cg-RX-API-DMAC7.html)
IL (1) IL304354A (cg-RX-API-DMAC7.html)
MX (1) MX2023008249A (cg-RX-API-DMAC7.html)
WO (1) WO2022153246A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306739B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3696495A (en) 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
PL362691A1 (en) 2000-12-15 2004-11-02 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
AU2003245442B2 (en) 2002-06-13 2009-02-05 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
WO2007056330A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CN102711739B (zh) * 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
KR102631986B1 (ko) * 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
CN110809471A (zh) * 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN111315736B (zh) * 2017-10-05 2023-07-07 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法
CA3106557A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態

Similar Documents

Publication Publication Date Title
JP5788331B2 (ja) 浸食マトリックス中に1またはそれ以上のフマル酸エステルを含む医薬製剤
JP5816091B2 (ja) ナトリウムオキシベートの即時放出投薬形態
JP6043281B2 (ja) 4−アミノ−5−フルオロ−3−[6−(4−メチルピペラジン−1−イル)−1h−ベンズイミダゾール−2−イル]−1h−キノリン−2−オンラクテート一水和物を含む医薬組成物
JP5351490B2 (ja) ニフェジピン含有有核錠剤およびその製法
JP4316013B2 (ja) エプロサルタン二水和物ならびにその製法および処方
JPH09143073A (ja) 持続性ニフエジピン製剤
US20180344695A1 (en) Sustained release pharmaceutical compositions
US20070059365A1 (en) Novel formulation of ropinirole
US20070104785A1 (en) Tablets of linezolid form iii and processes for their preparation
US10702520B1 (en) Pharmaceutical compositions of posaconazole
CA2361843C (en) Swallowable tablets with high content of n-acetylcysteine
JP5208729B2 (ja) 徐放性錠剤の製造方法
JP3751287B2 (ja) 小型化されたニフェジピン有核錠剤
EP2701689B1 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
WO2014006636A2 (en) Stable compositions of fesoterodine
WO2022225489A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
US20060002997A1 (en) Nitrofurantoin controlled release dosage form
CN101677960A (zh) 美金刚胺的药物组合物
KR101093781B1 (ko) pH조절제를 함유하는 목시플록사신 고형 조성물
JP2021518422A (ja) レナリドミドを含む医薬組成物
CN117815197A (zh) 一种瑞巴派特缓释制剂及其制备方法和应用
JP2025535941A5 (cg-RX-API-DMAC7.html)
WO1998046214A1 (en) Pharmaceutical tablet of amiodarone salt
US20080081069A1 (en) Novel controlled release formulations of divalproex sodium
RO132297A2 (ro) Compoziţie cu cefpodoxim proxetil cu eliberare extinsă